Treatment of lower-risk myelodysplastic syndromes
Myelodysplastic neoplasms (MDS) involve clonal hematopoiesis and cellular dysplasia, driven by genetic and epigenetic alterations. Spliceosome mutations and epigenetic dysregulation underscore the intricate pathogenesis of MDS. The bone marrow microenvironment, stromal dysfunction, chronic inflamma...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ferrata Storti Foundation
2024-10-01
|
| シリーズ: | Haematologica |
| オンライン･アクセス: | https://haematologica.org/article/view/11799 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|